Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × HER2-positive Breast Cancer × Biopsy × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 18 Prostatic Neoplasms 13 Carcinoma, Non-Small-Cell Lung 9 Neoplasms 7 Colorectal Neoplasms 7 Pancreatic Neoplasms 6 Melanoma 5 Lymphoma 4 Lung Neoplasms 4 Liver Neoplasms 4 Head and Neck Neoplasms 4 Esophageal Neoplasms 4 Colonic Neoplasms 4 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Salivary Gland Neoplasms 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Myelodysplastic Syndromes 3 Multiple Myeloma 3 Mouth Neoplasms 3 Kidney Neoplasms 3 Gastrointestinal Neoplasms 3 Gastritis, Atrophic 3 Barrett Esophagus 3 Adenocarcinoma Of Esophagus 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2

Interventions

pyrotinib 4 neratinib 2 tucatinib 1 trastuzumab deruxtecan 1 pertuzumab 1 Trastuzumab 1 Hospital Information Systems 1 Genetic Testing 1 Electronic Health Records 1 Blood Specimen Collection 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04288141 2022-11-14

HERdi PREDICT

King's College London

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡